当前位置: X-MOL 学术Indian J. Hematol. Blood Transfus. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Is it Worthwhile to Undergo the Extended Stage Assessment in Orbital and Ocular Adnexal MALT Lymphoma with Symptoms Limited to the Ocular Adnexa?
Indian Journal of Hematology and Blood Transfusion ( IF 0.7 ) Pub Date : 2021-04-26 , DOI: 10.1007/s12288-021-01429-6
Sungwoo Park 1 , Gyeong-Won Lee 1 , Myung Soo Hyun 2 , Kyung Hee Lee 2 , Sung Ae Koh 2 , Min Kyoung Kim 2
Affiliation  

Compared to ocular adnexal lymphoma of mucosa-associated lymphoid tissue-type (OAML) patients with symptoms related invasion beyond the ocular adnexa, the different approaches to staging assessment may be required in OAML patients with symptoms limited to the ocular adnexa. Seventy-six patients to be diagnosed with OAML and performed bone marrow biopsy and imaging study at Yeungnam University Hospital in 1995–2014 were enrolled. Patients with symptoms limited to the ocular adnexa were included. Computed tomography, magnetic resonance imaging, positron emission tomography (PET), and bone marrow biopsies were performed for diagnosis, NM staging and follow up evaluation. Most patients were treated with external beam irradiation (median dose, 30 Gray (Gy)). The relapse-free survival (RFS) was analyzed according to the tumor laterality and TNM stage. The median follow-up period was 72 months. The 5-year RFS and overall survival rates were 82.1% and 95.6% respectively. Of all 76 patients, lymph node and bone marrow involvement was identified in 1 patient, respectively. Among the 3 patients with T4 stage as tumor invasion beyond ocular adnexa, bone marrow involvement was confirmed in a patient with left cheek invasion. Only 11 of the 43 patients who underwent PET showed positive uptakes in orbital lesion. The patients with advanced stage were alive without recurrences. Bone marrow examination is useful in OAML patients with T4 for extended stage assessment. The AJCC TNM staging system was not significantly predictive factor for relapse, but may contribute to clarifying the patient group that needs bone marrow study.



中文翻译:

症状仅限于眼附件的眼眶和眼附件 MALT 淋巴瘤是否值得进行扩展阶段评估?

与症状相关浸润超出眼附件的粘膜相关淋巴组织型 (OAML) 患者的眼附件淋巴瘤相比,症状仅限于眼附件的 OAML 患者可能需要不同的分期评估方法。入选 1995-2014 年在岭南大学医院诊断为 OAML 并进行骨髓活检和影像学检查的 76 名患者。症状仅限于眼部附件的患者被包括在内。计算机断层扫描、磁共振成像、正电子发射断层扫描 (PET) 和骨髓活检用于诊断、NM 分期和随访评估。大多数患者接受外照射治疗(中位剂量,30 戈瑞 (Gy))。根据肿瘤偏侧性和TNM分期分析无复发生存期(RFS)。中位随访期为 72 个月。5 年 RFS 和总生存率分别为 82.1% 和 95.6%。在所有 76 名患者中,分别有 1 名患者出现淋巴结和骨髓受累。在3例T4期肿瘤侵犯眼附属器外的患者中,1例左侧颊部侵犯骨髓受累。接受 PET 的 43 名患者中只有 11 名在眼眶病变中显示阳性摄取。晚期患者均存活,无复发。骨髓检查可用于 T4 期 OAML 患者的扩展分期评估。AJCC TNM 分期系统不是复发的显着预测因素,但可能有助于明确需要进行骨髓研究的患者群体。5 年 RFS 和总生存率分别为 82.1% 和 95.6%。在所有 76 名患者中,分别有 1 名患者出现淋巴结和骨髓受累。在3例T4期肿瘤侵犯眼附件以外的患者中,1例左侧颊部侵犯骨髓受累。接受 PET 的 43 名患者中只有 11 名在眼眶病变中显示阳性摄取。晚期患者均存活,无复发。骨髓检查可用于 T4 期 OAML 患者的扩展分期评估。AJCC TNM 分期系统不是复发的显着预测因素,但可能有助于明确需要骨髓研究的患者群体。5 年 RFS 和总生存率分别为 82.1% 和 95.6%。在所有 76 名患者中,分别有 1 名患者出现淋巴结和骨髓受累。在3例T4期肿瘤侵犯眼附件以外的患者中,1例左侧颊部侵犯骨髓受累。接受 PET 的 43 名患者中只有 11 名在眼眶病变中显示阳性摄取。晚期患者均存活,无复发。骨髓检查可用于 T4 期 OAML 患者的扩展分期评估。AJCC TNM 分期系统不是复发的显着预测因素,但可能有助于明确需要骨髓研究的患者群体。分别。在3例T4期肿瘤侵犯眼附件以外的患者中,1例左侧颊部侵犯骨髓受累。接受 PET 的 43 名患者中只有 11 名在眼眶病变中显示阳性摄取。晚期患者均存活,无复发。骨髓检查可用于 T4 期 OAML 患者的扩展分期评估。AJCC TNM 分期系统不是复发的显着预测因素,但可能有助于明确需要骨髓研究的患者群体。分别。在3例T4期肿瘤侵犯眼附件以外的患者中,1例左侧颊部侵犯骨髓受累。接受 PET 的 43 名患者中只有 11 名在眼眶病变中显示阳性摄取。晚期患者均存活,无复发。骨髓检查可用于 T4 期 OAML 患者的扩展分期评估。AJCC TNM 分期系统不是复发的显着预测因素,但可能有助于明确需要骨髓研究的患者群体。晚期患者均存活,无复发。骨髓检查可用于 T4 期 OAML 患者的扩展分期评估。AJCC TNM 分期系统不是复发的显着预测因素,但可能有助于明确需要骨髓研究的患者群体。晚期患者均存活,无复发。骨髓检查可用于 T4 期 OAML 患者的扩展分期评估。AJCC TNM 分期系统不是复发的显着预测因素,但可能有助于明确需要骨髓研究的患者群体。

更新日期:2021-04-26
down
wechat
bug